Meanwhile, it is usually reported that crizotinib is generally well tolerated in patients with ALK-positive NSCLC, with most treatment-related adverse events of a grade 2 or less, including gastrointestinal disturbances and visual events [6]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.